AFRMJune 2, 2026 at 12:22 PM UTCFinancial Services

Affirm Partners with Stripe for UK BNPL Launch

Read source article

What happened

Affirm has expanded its partnership with Stripe to offer buy-now-pay-later solutions to U.K. merchants for the first time, marking a strategic international move. The collaboration leverages Stripe's extensive merchant network, potentially accelerating Affirm's GMV growth and diversifying revenue beyond the U.S. However, the company's stock already trades at over 100x trailing earnings and more than double a conservative DCF estimate, reflecting optimistic expectations. The DeepValue report highlights strong operational performance—first GAAP-profitable year, positive free cash flow—but warns of elevated leverage, thin interest coverage, and sector delinquency risks. This new partnership adds a growth catalyst, but it does not address the core valuation and balance sheet concerns that underpin the cautious stance.

Implication

Affirm's entry into the U.K. via Stripe is a logical extension of its platform and could boost long-term GMV, but the near-term financial impact is likely modest against a $23.9B market cap. The company's net debt/EBITDA of ~9x and interest coverage of 0.3x leave it vulnerable to funding or credit shocks. While the partnership supports the growth narrative, it does not mitigate the high multiples (P/E ~104x, EV/EBITDA ~43x) that already price in substantial success. Investors should watch for adoption metrics and funding cost trends in the U.K., but the core investment thesis remains one of limited margin of safety. The stock may rally on the news, but disciplined value investors would wait for a more attractive entry point or clear evidence of de-risking.

Thesis delta

The U.K.-Stripe partnership is an incremental positive that strengthens Affirm's growth outlook and international diversification. However, it does not shift the fundamental risk/reward calculus: the stock remains priced for perfection with high leverage and credit sensitivity. The thesis still leans toward caution until valuation or balance sheet risks improve materially.

Confidence

LOW